TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2442538
Drug: Intravenous enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enalaprilat (ET) 5 mg
Study: 2442538
Drug: Oral enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enalapril (E) 10 mg
Study: 2442538
Drug: Intravenous enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enalapril (E) 5 mg
Study: 2442538
Drug: Oral lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lisinopril (LI) 10 mg
Study: 2442538
Drug: Intravenous lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lisinopril (LI) 5 mg
Study: 29526707
Drug: Self-administered DMPA-SC
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered DMPA-SC
Study: 30894394
Drug: Provider-administered DMPA-SC
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-administered DMPA-SC
Study: 28241271
Drug: Pill bottle
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill bottle strip with toggles
Study: 20804848
Drug: Small sips
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small sips (5 mL)
Study: 20804848
Drug: Large sips
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large sips (20 mL)
Study: 18577289
Drug: Levodopa administration
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa administration (on condition)
Study: 18577289
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug administration (off condition)
Study: 14604194
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (1.4 g natural protein/kg target weight/day and 35 kcal/kg target weight/day)
Study: 14604194
Drug: Calcium caseinate
Normalized name: calcium caseinate
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium caseinate (0.7 g calcium caseinate plus 0.7 g natural protein diet/kg target weight/day and 35 kcal/kg target weight/day)
Study: 8450109
Drug: Behavioral marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral marital therapy
Study: 8450109
Drug: Insight-oriented marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight-oriented marital therapy
Study: 3300270
Drug: Weekly topical
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly topical APF treatment (1.2% fluoride)
Study: 3300270
Drug: Weekly topical
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly topical APF treatment (1.2% fluoride) and sodium fluoride (0.05%) mouthrinse, nightly rinse
Study: 30556832
Drug: NRT (Nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT (Nicotine Replacement Therapy)
Study: 26351027
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antihypertensive treatment (n=47)
Study: 26351027
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antihypertensive treatment (n=55)
Study: 17854523
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist administration (group B)
Study: 15129927
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg calcium citrate/400 I.U. Vitamin D)
Study: 11304901
Drug: Venlafaxine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (37.5 mg bid for 7 days, then 75 mg bid until Day 28)
Study: 11304901
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily for 28 days)
Study: 9345339
Drug: TNF 80
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF 80 micrograms/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks
Study: 9345339
Drug: TNF 40
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF 40 micrograms/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks
Study: 9345339
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TNF, IL-2, and IFN-alpha
Study: 3481160
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1.0 mM CuSO4 and 2.0 mM hexetidine
Study: 26537500
Drug: Supervised pharmacy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Supervised pharmacy student-led medication review
Study: 18622250
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg three times daily
Study: 24097128
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid 500 mg/125 mg three times daily
Study: 20381077
Drug: Amiodarone (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (n = 40), continuous infusion at a rate of 0.73 mg/min for 96 hours (total dose 4200 mg)
Study: 12823075
Drug: Low-dose risperidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose risperidone (starting dose of 0.25 mg/day, titrated upward to 2 mg/day)
Study: 1514347
Drug: Low-dose intramuscular
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intramuscular ketamine (1 mg/kg)
Study: 31319637
Drug: Pethidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (1 mg/kg)
Study: 6088248
Drug: CCNU, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU, cyclophosphamide, vincristine and methotrexate (CCOM) with consolidation locoregional radiation (30 Gy) after two courses of chemotherapy for LD patients.
Study: 6088248
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy after consolidation radiotherapy for a subset of 12 LD patients achieving CR.
Study: 27251974
Drug: EMD +
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD + ABG (combination group)
Study: 23387216
Drug: HX0507 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX0507 (3 mg/kg and 8 mg/kg or above)
Study: 17175564
Drug: Warfarin (dose-adjusted,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted, INR 2.0-3.0)
Study: 11853280
Drug: Menatetrenone-4 plus
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone-4 plus elemental calcium carbonate 800 mg/day
Study: 11853280
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium carbonate 800 mg/day
Study: 9596112
Drug: ABT-761 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-761 (200 mg orally, 5 h prior to exercise)
Study: 7816491
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (group S, n = 14) received 0.5% lidocaine plus triamcinolone acetonide (10 mg/ml).
Study: 7816491
Drug: Steroid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid plus morphine group (group S + M, n = 10) received the same combination plus 2.5 mg of morphine sulphate.
Study: 3354495
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of retinyl palmitate (100,000 IU, or 30 mg retinol equivalent)
Study: 3354495
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A injections
Study: 23742659
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein (HP) yogurt (14.0 g protein)
Study: 23742659
Drug: Normal Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Protein (NP) yogurt (5.0 g protein)
Study: 19376240
Drug: Low-dose endotoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose endotoxin (females)
Study: 19376240
Drug: Low-dose endotoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose endotoxin (males)
Study: 15848571
Drug: Sirolimus (SL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SL) 3 mg/d for African Americans; 2 mg/d for others, starting on days 2 and 3, adjusted to 8 to 10 ng/d by weeks 3 to 4 posttransplant.
Study: 15848571
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) levels 15 to 20 ng/mL, progressively reduced to 5 ng/mL by 3 months.
Study: 15848571
Drug: Basiliximab (BX)
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab (BX) induction, TAC, and steroids without SL (Group 2).
Study: 30528227
Drug: rhHNS IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhHNS IT 45 mg administered every 2 weeks (Q2W)
Study: 30528227
Drug: rhHNS IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhHNS IT 45 mg administered every 4 weeks (Q4W)
Study: 28068956
Drug: Beta-lactam monotherapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam monotherapy
Study: 25830421
Drug: Beta-lactam-macrolide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam-macrolide combination therapy
Study: 28068956
Drug: Fluoroquinolone monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone monotherapy
Study: 23850227
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion (4 mg)
Study: 21463520
Drug: intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive treatment plus the facilitator‐led individual behaviour change intervention (n = 239)
Study: 21463520
Drug: intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive treatment alone (n = 239)
Study: 19826393
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 2.5 mg injections at 4-week intervals
Study: 16478882
Drug: Consolidation CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation CT (chemotherapy)
Study: 14739801
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration (7 ml/kg hydroxyethyl starch)
Study: 14739801
Drug: Vasopressor (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressor (0.2 mg/kg ephedrine)
Study: 11282812
Drug: External self-exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External self-exposure treatment
Study: 11282812
Drug: Interoceptive self-exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interoceptive self-exposure treatment
Study: 11282812
Drug: Combined external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined external and interoceptive self-exposure treatment
Study: 9093301
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of five-valent pneumococcal conjugate vaccine (PCV)
Study: 7653738
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine (eye-drops and nasal spray)
Study: 27363578
Drug: Oral loratadine
Normalized name: loratadine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loratadine
Study: 3150824
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of luteinizing hormone‐releasing analogue (GnRHa, Buserelin) and pulsatile administration of hMG (Group I)
Study: 3150824
Drug: Pulsatile hMG
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile hMG administration alone (Group II)
Study: 28816509
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (MAS) 12.5-25 mg
Study: 23477890
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg IV four times per week)
Study: 18158380
Drug: Sleep Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep Deprivation (SD) therapy (six nights of total SD, separated by recovery sleep)
Study: 18158380
Drug: No Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Sleep Deprivation therapy (Control group)
Study: 16419700
Drug: Nimeisulide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimeisulide (oral administration)
Study: 16419700
Drug: 654-2 (injection)
Normalized name: isopropyl alcohol 0.654 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 654-2 (injection)
Study: 26569059
Drug: Weekly methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly methotrexate (MTX)
Study: 36066
Drug: Compound A
Normalized name: Compound A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound A (Actified)
Study: 36066
Drug: Compound B
Normalized name: Compound B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound B (Dristan)
Study: 31449573
Drug: No membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: No membrane on buccal overlay graft, ADMG used only to cover the occlusal surface.
Study: 28241247
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg every 6 hours)
Study: 24218952
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills (6 g tid) combined with bromocriptine
Study: 15610569
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine hydrochloride gel (20 mL of 2% lidocaine gel administered 15 minutes before biopsy)
Study: 15610569
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL of ultrasound gel administered under the same conditions)
Study: 15610569
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine hydrochloride gel
Study: 11460891
Drug: Oxcarbazepine monotherapy
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine monotherapy (2400 mg/day)
Study: 11460891
Drug: Oxcarbazepine adjunctive
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine adjunctive therapy (600, 1200, 2400 mg/day)
Study: 11460891
Drug: Oxcarbazepine monotherapy
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine monotherapy
Study: 16615036
Drug: Oxcarbazepine adjunctive
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine adjunctive therapy
Study: 11460891
Drug: Oxcarbazepine treatment
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine treatment
Study: 10936472
Drug: High-dose willow
Normalized name: Willow bark
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose willow bark extract (240 mg salicin)
Study: 10936472
Drug: Low-dose willow
Normalized name: Willow bark
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose willow bark extract (120 mg salicin)
Study: 8725599
Drug: H2 blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blocker (famotidine 20mg orally at 9 pm the day before and 2hs before anesthesia)
Study: 8725599
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no eating or drinking from 9 pm the day before surgery, 500 ml maintenance fluid before anesthesia)
Study: 7842188
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg
Study: 30527263
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (3.0 g/d of eicosapentaenoic acid and docosahexaenoic acid)
Study: 22728482
Drug: Adefovir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir plus Entecavir (ADV + ETV) combination therapy
Study: 18461609
Drug: Adefovir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir monotherapy
Study: 22728482
Drug: Adefovir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir plus Lamivudine (ADV + LAM) therapy
Study: 16042643
Drug: LAAM (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM (three doses per week)
Study: 16042643
Drug: Methadone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (daily dosing)
Study: 15117045
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celecoxib
Study: 2280233
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (20 ml daily for 6 weeks)
Study: 30787899
Drug: Daily 10-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 10-min classroom-based exercise break of moderate to vigorous intensity for 9 weeks
Study: 17765354
Drug: Single-agent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent docetaxel (D) - docetaxel 100mg/m² on day 1
Study: 10786204
Drug: Fenoterol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (4 x 100 mcg daily)
Study: 10786204
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (4 x 40 mcg daily)
Study: 9863162
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) of β‐carboxyethylgermanium sesquioxide (Ge‐132) 1 g · m‐2
Study: 9863162
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (MD) of β‐carboxyethylgermanium sesquioxide (Ge‐132) 2.5 g · m‐2
Study: 9863162
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) of β‐carboxyethylgermanium sesquioxide (Ge‐132) 4 g · m‐2
Study: 6340909
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg extended-release fenfluramine
Study: 31743103
Drug: Child-parent relationship
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-parent relationship therapy (CPRT) in 10 sessions for 45-60 minutes each
Study: 28440045
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg BID + Phentermine 15 mg QD
Study: 28440045
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg BID + Phentermine 15 mg BID
Study: 24846935
Drug: Beta-lactam and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam and macrolide combination therapy
Study: 7862273
Drug: CT angiography
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT angiography (CTA) using 60 cc of contrast (medium 2 cc/sec) with 5 mm slices, reconstructed at 3 mm slice thickness (Group 1)
Study: 7862273
Drug: CT angiography
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT angiography (CTA) using 90 cc of contrast (medium 3 cc/sec) with 3 mm slices, reconstructed at 1 mm slice thickness (Group 2)
Study: 2675587
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30, 60 or 90 mg administered once daily
Study: 11834646
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of furosemide
Study: 7723928
Drug: Acetyl-L-carnitine
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine
Study: 30792037
Drug: Nystatin-neomycin-polymyxin B
Normalized name: neomycin / polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin-neomycin-polymyxin B combination (NNP) for 12 days
Study: 30792037
Drug: Nystatin-neomycin-polymyxin B
Normalized name: neomycin / polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin-neomycin-polymyxin B combination (NNP)
Study: 21542956
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (30 mg/kg)
Study: 15179180
Drug: Modafinil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (4 mg x kg)
Study: 12562588
Drug: Prazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (mean dose=9.5 mg/day at bedtime, SD=0.5)